Zepbound Cost: List Price, Insurance, and Savings Context

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Trying to make sense of what Zepbound costs? The PlexusDx Education Hub breaks down pricing drivers, coverage, and the genetics behind metabolic care. Open the Peptides & GLP-1 library to start.

Cost is one of the most searched questions in the GLP-1 space, and the honest answer is that no single figure captures it. What you pay depends on insurance coverage, the indication your prescription is written for, savings card eligibility, pharmacy pricing, and whether a compounded alternative is available. This page lays out the published list price, the coverage variables, the savings mechanisms, and the factual reasons the numbers online swing so widely.

A useful mental model up front: think of cost as a stack rather than a single price tag. At the bottom sits the manufacturer list price, and on top of it sit insurance decisions, prior authorization rules, savings programs, and pharmacy-level variation, each of which can move the final number up or down. Two people can face very different out-of-pocket costs for the same medication because their stacks differ. The sections below take that stack apart layer by layer.

The published list price

Zepbound list price is approximately $1,059 per month at U.S. list as of April 2026, per Eli Lilly's published pricing. That figure is the starting point, not the destination. List price is rarely what most insured patients actually pay, because insurance, rebates, manufacturer savings cards, and pharmacy negotiation all sit between the list number and the counter. Out-of-pocket cost shifts with your plan, formulary, prior authorization, and the indication on the prescription.

Insurance and prior authorization

Commercial coverage hinges on whether the prescription is written for an FDA-approved indication and on your plan's specific formulary and prior authorization rules. Many commercial plans cover GLP-1 receptor agonists for type 2 diabetes. Coverage for chronic weight management is more variable, is frequently gated behind BMI-based prior authorization, and is excluded outright by some plans. Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products. Confirm details directly with your plan.

Manufacturer and pharmacy savings

Eli Lilly publishes a manufacturer savings card program that can substantially reduce monthly out-of-pocket cost for eligible commercially-insured patients. Eligibility typically excludes Medicare, Medicaid, TRICARE, and other government-funded insurance, and the cards carry monthly and annual caps whose terms change over time. Independent pharmacy discount platforms such as GoodRx and SingleCare publish coupon prices that vary by pharmacy. Verify current terms on the manufacturer's site at the time of fill.

Compounded alternatives and what changed

During the FDA-declared shortages, 503A compounding pharmacies legally produced compounded semaglutide and tirzepatide. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, narrowing the compounding window without eliminating all legitimate activity. Compounded formulations remain available through licensed pathways where clinically justified, and they are priced separately from the brand because they are not identical to FDA-approved products.

What real-world scenarios look like

A few illustrative situations: with commercial insurance that covers the indication and the savings card applied, eligible patients may pay as little as $25 per month depending on plan terms and caps. With commercial insurance that does not cover the indication, cash-pay costs land closer to list price minus any coupon. Without insurance, costs approach list price, while compounded alternatives through the PlexusDx Weight Management Protocols follow a separate published pricing structure.

The genetic context behind the spend

Before committing budget, it is worth understanding your metabolic baseline. Variants in FTO, MC4R, and GLP1R influence appetite, satiety, and receptor biology. These pathway-level traits describe tendencies, not medication outcomes. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights so that context informs the decision, as education rather than a prediction of drug response.

Frequently Asked Questions

How much does Zepbound cost per month?

List price is approximately $1,059 per month at U.S. list as of April 2026, per Eli Lilly's published pricing. Insurance, savings cards, and pharmacy pricing can substantially change what a patient actually pays. Confirm the current price with the pharmacy before filling the prescription, since terms shift over time.

Will insurance cover it?

It depends on your plan, formulary, the FDA indication on the prescription, and prior authorization criteria. Many commercial plans cover GLP-1 receptor agonists for type 2 diabetes, while chronic weight management coverage is more variable. Medicare does not cover weight-management indications for weight alone as of April 2026.

Are there coupons or savings cards?

Eli Lilly publishes a manufacturer savings card for eligible commercially-insured patients, and independent platforms like GoodRx publish discount prices that vary by pharmacy. Government-insurance patients are typically excluded from manufacturer cards. Check the manufacturer site at the time of fill, because eligibility and caps change.

Are there lower-cost alternatives?

Licensed compounding pharmacies produce compounded semaglutide and tirzepatide at separate price points from the brand, though these are legally and factually different products, not generics. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols with published per-protocol pricing on each product page.

For more on pricing, coverage, and the genetics behind metabolic care, return to the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.